Investment Research & Advisory Group Inc. Sells 296 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Investment Research & Advisory Group Inc. lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.7% during the fourth quarter, Holdings Channel reports. The fund owned 17,547 shares of the medical research company’s stock after selling 296 shares during the period. IQVIA makes up 1.0% of Investment Research & Advisory Group Inc.’s holdings, making the stock its 20th largest holding. Investment Research & Advisory Group Inc.’s holdings in IQVIA were worth $3,448,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in IQV. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the third quarter worth $27,000. Park Place Capital Corp bought a new stake in IQVIA in the 3rd quarter valued at about $28,000. Avior Wealth Management LLC grew its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares in the last quarter. Assetmark Inc. increased its holdings in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Finally, UMB Bank n.a. raised its position in shares of IQVIA by 74.4% in the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after buying an additional 99 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of several analyst reports. Stephens began coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Bank of America cut their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. BTIG Research reduced their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Stock Performance

Shares of IQVIA stock opened at $204.54 on Friday. The stock has a market cap of $37.12 billion, a price-to-earnings ratio of 26.84, a P/E/G ratio of 2.14 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company’s fifty day moving average is $199.71 and its 200 day moving average is $221.06.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.